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Abstract
Molecular events leading to epithelial ovarian cancer are poorly understood but ovulatory hormones and a high number of
life-time ovulations with concomitant proliferation, apoptosis, and inflammation, increases risk. We identified genes that are
regulated during the estrous cycle in murine ovarian surface epithelium and analysed these profiles to identify genes
dysregulated in human ovarian cancer, using publically available datasets. We identified 338 genes that are regulated in
murine ovarian surface epithelium during the estrous cycle and dysregulated in ovarian cancer. Six of seven candidates
selected for immunohistochemical validation were expressed in serous ovarian cancer, inclusion cysts, ovarian surface
epithelium and in fallopian tube epithelium. Most were overexpressed in ovarian cancer compared with ovarian surface
epithelium and/or inclusion cysts (EpCAM, EZH2, BIRC5) although BIRC5 and EZH2 were expressed as highly in fallopian
tube epithelium as in ovarian cancer. We prioritised the 338 genes for those likely to be important for ovarian cancer
development by in silico analyses of copy number aberration and mutation using publically available datasets and identified
genes with established roles in ovarian cancer as well as novel genes for which we have evidence for involvement in ovarian
cancer. Chromosome segregation emerged as an important process in which genes from our list of 338 were over-
represented including two (BUB1, NCAPD2) for which there is evidence of amplification and mutation. NUAK2, upregulated
in ovarian surface epithelium in proestrus and predicted to have a driver mutation in ovarian cancer, was examined in a
larger cohort of serous ovarian cancer where patients with lower NUAK2 expression had shorter overall survival. In
conclusion, defining genes that are activated in normal epithelium in the course of ovulation that are also dysregulated in
cancer has identified a number of pathways and novel candidate genes that may contribute to the development of ovarian
cancer.
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Introduction
Epithelial ovarian cancer is the fifth most common cause of
cancer death in women in the Western world and the leading
cause of death from gynaecological malignancies. Despite the
magnitude of this clinical problem, little is known about the
mechanism of neoplastic transformation. Currently, insight into
the pathogenesis of ovarian cancer comes from known factors that
increase risk. These include inherited mutations in the BRCA1/2
genes in a minority of cases, and a range of hormone and/or
reproduction related factors more generally [1,2]. In the latter
case, hormone replacement therapy and a high cumulative
number of life-time ovulations with few episodes of anovulation
due to pregnancy, oral contraceptive use or breast feeding have
been associated with increased risk. Conversely, ovarian cancer
risk is reduced by more live-births, long-term breast feeding and
oral contraceptive use [3].
The biological basis for altered risk associated with hormonal
and reproductive factors is essentially unknown, although several
hypotheses have been proposed. The first, the ‘incessant ovulation
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15hypothesis’, posits that ovulation and its sequelae increases the
likelihood of malignancy [1], and that pregnancies and oral
contraceptives are protective because they suppress ovulation [4].
The second hypothesis is that circulating levels of gonadotropins
increase the risk of malignancy and that pregnancy and oral
contraceptive use protect by suppressing secretion of these
hormones [5]. Excessive levels of gonadotropins, LH and FSH,
related to the surge occurring during ovulation, are proposed to
contribute to ovarian cancer development. The loss of gonadal
negative feedback at menopause, resulting in peak concentrations
of FSH and LH at the age when the incidence of ovarian cancer
climbs dramatically, provides support for the gonadotropin
hypothesis [6] and LH levels have been reported to be elevated
in BRCA1 mutation carriers in the follicular phase compared with
non-carriers, suggesting that high levels of LH may contribute to
BRCA-associated increased risk of ovarian cancer [7]. Protection
afforded by multiple pregnancies and long-term oral contraceptive
use provides some support for the gonadotropins theory as both
factors are associated with low levels of gonadotropins as well as
the inhibition of incessant ovulation. However, the level of
protection conferred by pregnancy and oral contraceptive use,
has been suggested to be greater than that from inhibition of
ovulation alone [2] and a third potential explanation based on
epidemiological data is that the ovarian surface epithelium is
protected from malignant transformation by exposure to proges-
terone or progesterone analogues during pregnancy or in oral
contraceptives [2,8].
Although it is widely believed that serous ovarian cancers arise
from the ovarian surface epithelium and inclusion cysts formed
when ovarian surface epithelium become trapped inside the ovary
[9], a more recent hypothesis for the initiation of ovarian cancer
suggests that precursor lesions exist in the fimbriated end of the
fallopian tube epithelium [10]. It is possible that fallopian tube
epithelium become trapped within the ovarian stroma during
healing of the ovulatory wound where the high hormonal milieu
may cause malignant transformation in a manner akin to the
hypothesis for inclusion cysts [9]. Support for the initiation of
ovarian cancer in fallopian tube epithelium can be found from
studies which show that there are similarities in gene expression
profiles of serous ovarian cancer and fallopian tube epithelium, yet
these differ to the profiles observed for ovarian surface epithelium
[11]. It is unclear, however, whether this is evidence of initiation in
the fallopian tube epithelium or of differentiation of ovarian
cancer towards a fallopian tube-like phenotype which is a defining
morphological characteristic of serous ovarian cancer.
Tone et al. [11] found that gene expression profiles of fallopian
tube epithelium from BRCA mutation carriers in the luteal phase
were more similar to expression profiles of serous ovarian cancer
than fallopian tube epithelium from carriers in the follicular phase.
Similarly, xenograft studies have shown that xenografts of ovarian
cancer are more likely to become established if they are implanted
during the proestrus phase of the murine estrous cycle, when
hormone levels peak [12]. These data suggest that susceptibility of
ovarian surface epithelium and/or fallopian tube epithelium to
malignant transformation may change throughout the estrous
cycle presumably in response to fluctuating hormones, and is
further evidence of a role for the menstrual cycle on ovarian
cancer development.
We recently identified gene signatures associated with ovarian
surface epithelium during different stages of the murine estrous
cycle [13]. We reasoned that these genes which are differentially
expressed in ovarian surface epithelium through the estrous cycle
are likely to be hormone regulated and potentially involved in
processes related to ovulation, including cell proliferation,
apoptosis and inflammation. Dysregulation of pathways under-
pinning each of these processes has been implicated in neoplastic
transformation of various tissue types. We hypothesised that a
subset of genes involved in normal ovarian epithelial cell functions
are also consistently aberrantly expressed in ovarian cancer and
identification of this subset would assist in prioritising human
candidate genes and pathways implicated in progression to
ovarian cancer.
The aim of this study was to determine whether genes regulated
during the estrous cycle and involved in normal ovarian function
play a role in the progression of normal epithelial cells to ovarian
cancer. To do this, the list of genes that was differentially expressed
in ovarian surface epithelium over the estrous cycle, was cross-
matched against genes with reported aberrant expression in
ovarian cancer. For common genes, the expression of a number of
candidates was determined by immunohistochemistry in normal
ovarian surface epithelial cells, inclusion cysts, fallopian tube and
ovarian cancer samples. In addition, a relationship between gene
expression and copy number, and the presence of mutations in
ovarian cancer was examined using existing datasets. This
approach identified a number of individual candidate genes and
pathways that may be involved in the pathogenesis of ovarian
cancer.
Materials and Methods
Ethics statement
This study was approved by the Human Research Ethics
Committees of Sydney West Area Health Service and the
University of Sydney; protocol reference number: HREC2006/
2/4.21(2293). Written informed consent was obtained from all
participants in this study.
Expression microarray analysis of murine ovarian
epithelium
The expression array analysis of murine ovarian surface
epithelium has previously been described in detail [13]. Briefly,
total RNA (Stratagene Absolutely RNAH Nanoprep or Microprep
Kit, Stratagene, La Jolla, CA), was extracted from laser
microdissected ovarian surface epithelium (P.A.L.M Robot-
Microbeam system, Microlaser Technologies) from BALB/c mice
at 27 days of age (immature; n=4) and 10–13 weeks of age during
the estrous cycle, at proestrus (n=4) and estrus (n=4) [13].
Microarray slides comprising ,15,000 expressed sequence tags
from the National Institute of Ageing 15 K mouse clone library
(Australian Genome Research Facility, Melbourne, Australia)
were hybridized with Cy3- and Cy5-labeled cDNA generated
from double-amplified RNA. Estrous stage-specific gene expres-
sion profiles were obtained by direct comparison of ovarian
surface epithelium from immature mice and mice culled on
proestrus evening (2200 h) and estrus morning (1000 h) [13].
Ovarian cancer gene expression array profiles
To identify genes regulated during the estrous cycle that are
expressed in human ovarian carcinoma, we compared our
ovulation-related gene signature [13] with our own published
gene expression profiles of ovarian cancer [14–16] as well as those
from other selected published studies [17,18]. We examined
published studies on large-scale gene expression profiling of
ovarian cancer specimens published up to August 2009 using
PubMed (http://www.pubmed.com), and chose a subset of studies
based on the number and histological subtype of ovarian cancer
cases (serous cancer was preferred), similarity of microarray
platform used and similarity of the normal reference (ovarian
Common Expression in Ovarian Epithelium and Cancer
PLoS ONE | www.plosone.org 2 March 2011 | Volume 6 | Issue 3 | e17617surface epithelium was preferred over whole ovary or cell lines).
Studies which did not publish unique gene identifiers or which
analysed cell lines were excluded.
All of the chosen datasets reported genes differentially expressed
compared to a normal reference except for Tothill et al. [16]. We
determined the genes differentially expressed in the ovarian cancer
cases examined in Tothill et al. [16] by comparing the expression
profiles to data from ovarian surface epithelium brushings pooled
from ten patients generated on the same array platform [14].
Array data from both cohorts were RMA normalised together
using the R package ‘‘affy’’. Genes that were differentially
expressed between ovarian cancer and normal were determined
using significance analysis of microarrays [19] where all probes
with q-value,5% and fold change .2 were selected as
differentially expressed genes. Genes were classified as ‘dysregu-
lated’ in ovarian cancer if they fulfilled the above criteria.
Comparison of murine ovarian surface epithelium and
human ovarian cancer gene expression profiles
Human orthologs of the 905 murine genes found to be
differentially expressed in ovarian surface epithelium during the
estrous cycle [13] were identified using the list of mouse-human
orthologous genes available from the Mouse Genome Informatics
database (http://www.informatics.jax.org; accessed Sept 2009).
Genes regulated during the estrous cycle which were also
dysregulated in ovarian cancer were then identified by matching
Entrez Gene IDs and all gene symbols converted to HUGO gene
nomenclature symbols. Our final list comprised genes that were
regulated during the estrous cycle and shown to be dysregulated in
ovarian cancer compared to normal in at least one ovarian cancer
dataset.
Pathway and gene ontology analysis
MetaCore software (St. Joseph, MI, USA) was used to identify
the cellular pathways implicated by genes regulated in the estrous
cycle and dysregulated in ovarian cancer and to examine whether
gene ontologies were statistically over-represented in these gene
sets.
Patient tissue specimens
Details of the patient cohort can be found in Table 1. Cohort 1
consisted of formalin fixed paraffin embedded tissue samples of i)
serous ovarian cancer from previously untreated patients (n=20),
ii) normal ovary (n=10) and matching fallopian tubes (n=9) from
patients who had undergone a prophylactic salpingo-oophorecto-
my based on a strong family history (n=6) or who underwent
surgery for other non-malignant gynaecological diseases (n=4),
including contralateral benign ovarian tumors in two cases.
Cohort 2 comprised 96 cases of serous ovarian cancer with serous
ovarian tumor tissue represented on a tissue microarray which
included five cases from Cohort 1. The histopathology of
representative sections from all cases was reviewed by experienced
pathologists (RS and RB) to confirm the diagnosis, histological
subtype and to grade the carcinoma cases using standardised
criteria [20] as well as to identify tumor areas for construction of
the tissue array. Core biopsies (1 mm) of paraffin embedded tumor
areas were incorporated into a tissue microarray with 1.5 mm
between core centres using a manual arrayer (MTA-II, Beecher
Instruments, WI, USA). Each case was represented once on the
tissue microarray. A section from the tissue microarray was stained
with haematoxylin and eosin to confirm the inclusion of tumor
tissue in each core and cores without tumor were excluded from
analysis.
Clinical Definitions. Surgical staging was assessed in
accordance with International Federation of Gynaecological
Oncologists classification. Progression-free survival was defined
as the time interval between the date of histological diagnosis and
the first confirmed sign of disease recurrence or progression based
on definitions developed by the Gynaecological Cancer Intergroup
as previously described [21]. In the majority of cases the date of
progression was assigned using CA125 criteria. In cases where
CA125 was not a marker, or progression preceded an increase in
CA125, relapse was based on imaging (appearance of new lesion),
or, in a minority of cases, global deterioration in health status
attributable to the disease. Overall survival was calculated from
the date of histological diagnosis to the date of death and censored
at last contact date if the patient was alive.
Immunohistochemistry
Formalin-fixed paraffin embedded sections (3 mm) were mount-
ed on Superfrost Plus microscope slides (Lomb Scientific, NSW,
Australia) and dried at 37uC for 1 hr. Sections were dewaxed in
histolene and rehydrated through graded ethanols, before being
rinsed in water. Slides were then stained with the appropriate
antibody using the EnVision+HRP dual link kit (DAKO,
Glostrup, Denmark), according to manufacturer’s instructions.
Briefly, sections were subjected to antigen retrieval using Target
Retrieval Solution (DAKO, Glostrup, Denmark) before treatment
with 3% H2O2 for 10 min. Following consecutive rinses with
water and PBS, sections were incubated with primary antibody
diluted in PBS/0.1% Tween-20 using the dilutions and incubation
conditions indicated in Table 2. After rinsing in PBS/0.1%
Tween-20 and PBS, sections were incubated for 30 min at room
temperature with the Labeled Polymer-HRP solution and then
rinsed as previous. Bound antibody was visualised using diamino-
benzidine (DAKO, Glostrup, Denmark) prepared according to the
manufacturer’s instructions. Sections were exposed to diamino-
benzidine for 1–2 min and the reaction was stopped in water.
Sections were counterstained with Harris’ haematoxylin (Amber
Scientific, WA, Australia) before dehydration through graded
ethanols. Sections were air dried before clearing with histolene and
mounting with normount (Fronine, NSW, Australia). To control
for non-specific staining, adjacent sections were stained as above,
without the primary antibody.
Image analysis
Stained sections were analysed using TissueMap (Definiens,
Munich, Germany). Briefly, ovarian surface epithelium and
inclusion cysts in each section of normal ovary were identified
for analysis. A user-defined TissueMap algorithm was used to
identify regions of fallopian tube epithelium and tumor tissue
based on cell density. Identified areas of ovarian surface
epithelium, inclusion cysts, fallopian tube epithelium and tumor
tissue were then analysed for the intensity and extent of staining
and a histoscore calculated as follows: (% strongly stained
cells63)+(% moderately stained cells62)+(% weakly stained
cells61)/100, such that scores between 0 and 1 indicated weak
staining; 1 and 2 indicated moderate staining; and 2 and 3
indicated strong staining.
Analyses of copy number aberration and mutation
We compared genes regulated in the estrous cycle and
dysregulated in cancer to genes located in regions of copy number
aberration (CNA) using data from The Cancer Genome Atlas
(TCGA) (http://cancergenome.nih.gov) and a meta-analysis of
SNP-based CNA analysis in 398 primary epithelial ovarian cancer
samples [22]. Genes within regions of gain (log2 copy number ratio
Common Expression in Ovarian Epithelium and Cancer
PLoS ONE | www.plosone.org 3 March 2011 | Volume 6 | Issue 3 | e17617.0.3) or loss (log2 copy number ratio ,20.3) in greater than 30%
of samples in the Broad dataset were downloaded from TCGA
data browser (http://tcga-portal.nci.nih.gov/tcga-portal/Anom-
alySearch.html). Gorringe et al. [22] reported genes within ‘peak’
regions of copy number change as determined by ‘Genomic
Identification of Significant Targets in Cancer’ [23] in a subset of
240 samples. ‘Peaks’ represent statistically significant regions of
minimal gain or loss, considering both the frequency and
amplitude of copy number change, compared to a calculated
background aberration rate. Genes within regions of gain (log2
copy number ratio .0.3) or loss (log2 copy number ratio ,20.3)
in greater than 30% of samples were also reported.
We also compared genes regulated in the estrous cycle and
dysregulated in cancer to genes commonly mutated in cancer
using two previously published datasets [24,25] as well as the
COSMIC database (http://www.sanger.ac.uk/genetics/CGP/
cosmic). Futreal et al. [24] compiled a consensus list of genes in
which mutations contribute to tumorigenesis, while Greenman
et al. [25] screened 518 protein kinase genes and identified an
estimated 119 genes with ‘driver’ mutations.
Statistical analysis
All data were analysed using SPSS (version 16, SPSS, Inc) and a
5% significance level was used throughout. A Chi-square test was
used to determine i) if there was a significant overlap in genes
differentially expressed in murine ovarian surface epithelium during
the estrous cycle and genes differentially expressed in epithelial
ovarian cancer compared with normal, and ii) if there was a
correlation between gene copy number aberration and direction of
differential expression. Paired two-tailed t-tests were used to
compare histoscores of ovarian surface epithelium, inclusion cysts
and fallopian tube epithelium while a one-way analysis of variance
with least squares difference post hoc analysis was used for
comparisons with ovarian cancer histoscores. Associations between
histoscores and progression-free or overall survival were determined
using Kaplan-Meier curves with log-rank test.
Table 1. Patient characteristics and clinicopathological features of the cohorts used for immunohistochemical analysis.
Cohort 1 Cohort 2
Ovarian cancer Normal Ovarian cancer tissue microarray
Number of samples 20 10 96
Median patient age at surgery (range) 60.5 (37–77) 50 (40–60) 57 (22–84)
Histopathological grade
1
1 4 (20%) - 8 (8%)
2 3 (15%) - 46 (48%)
3 13 (65%) - 42 (44%)
Stage
2
I 5 (25%) - 3 (3%)
II 1 (5%) - 5 (5%)
III 10 (50%) - 78 (81%)
IV 4 (20%) - 10 (10%)
1Universal grading system [20].
2Surgical stage according to International Federation of Gynaecological Oncologists criteria.
doi:10.1371/journal.pone.0017617.t001
Table 2. Details of primary antibodies used.
Antigen Gene Symbol Supplier Catalogue or Clone No. Dilution Incubation conditions
Epithelial cell adhesion molecule EPCAM Abcam (Cambridge, MA) clone VU-1D9 1:100 1 hr at RT
1
Baculoviral IAP repeat-containing 5 BIRC5 Novus Biologicals (Littleton,
CO)
NB500-201 1:100 1 hr at RT
Mitogen-activated protein kinase 1 MAPK1 Abcam (Cambridge, MA) clone E460 1:50 1 hr at RT
Enhancer of zeste homolog 2 EZH2 Zymed (San Francisco, CA) 18-7395 1:50 1 hr at RT
Lipocalin 2 LCN2 Abcam (Cambridge, MA) clone HYB 211-01 1:400 1 hr at RT
SWI/SNF related, matrix associated,
actin dependent regulator of
chromatin, subfamily a, member 4
SMARCA4 Sigma (St. Louis, MO) B8184 1:200 1 hr at RT
p21 protein (Cdc42/Rac)-activated
kinase 2
PAK2 Epitomics (Burlingame, CA) 1721-1 1:50 4uC overnight
NUAK family, SNF1-like kinase, 2 NUAK2 Abgent (San Diego, CA) AP7158a 1:100 4uC overnight
1RT; room temperature.
doi:10.1371/journal.pone.0017617.t002
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Ovarian cancer gene expression profiles
We used five publically available ovarian cancer gene
expression datasets in our analysis. The selected studies were of
either predominantly or exclusively serous subtype, with relatively
large numbers of cases, all analysed on an Affymetrix platform and
most utilizing ovarian surface epithelium brushings for expression
comparison. Details of the published studies are provided in
Table 3. The cases analysed were mostly high grade, late stage
tumors and where possible we excluded data from borderline and
non-serous carcinomas (Table 3). We included results generated
from Heinzelmann-Schwarz et al. [17] in our analysis, despite the
fact that they compared ovarian cancer tissue to normal whole
ovaries, since they integrated their results with 13 other published
ovarian cancer expression studies and these results are likely to
represent genes consistently highly expressed in ovarian cancer.
Importantly, Lu et al. [18] and Heinzelmann-Schwarz et al. [17]
only reported genes that were up-regulated in ovarian cancer
which introduced a bias into our analyses.
The total number of genes differentially expressed in ovarian
cancer in at least one of the five datasets was 7285. Despite similar
cohorts and array platforms there was very little overlap between
the datasets - only two genes were overexpressed compared with
normal in all five studies (CD24, MAL2) and only 14 were
upregulated in four of the five studies (Table 4). There were 133
genes that were consistently downregulated in the three studies
that reported downregulation. The 15 genes with expression that
was lowest in ovarian cancer compared with normal are shown in
Table 4.
Estrous cycle regulated genes with aberrant expression
in ovarian adenocarcinoma
Previously we reported global gene expression changes in pure
populations of normal mouse ovarian surface epithelium from
immature mice (low hormone levels), cycling mice at proestrus
evening (high hormone levels just prior to ovulation), and at estrus
morning (low hormone levels just after ovulation) [13]. We found
905 genes regulated, the majority (n=502; 55%) being regulated
on proestrus evening, just prior to ovulation, co-incident with the
surge in ovulatory hormones [13]. We compared this list of 905
genes to the 7285 human candidate ovarian cancer genes selected
from the five published datasets. Overall, 338 genes that are
regulated during the estrous cycle were dysregulated in human
ovarian cancer specimens which is a significantly greater overlap
than would be expected by chance alone (p,0.0001, Chi square
test). Two estrous regulated genes, EPCAM and KIAA0101, were
identified in four of the five published ovarian cancer datasets and
25 genes were identified in three out of five human studies
(Table 5), the majority being upregulated in cancer. Almost half of
Table 3. Published transcription profiling studies used for comparison with mouse ovarian surface epithelium gene profiles.
Tothill et al. [16] Bonome et al. [14] Donninger et al. [15] Lu et al. [18]
Heinzelmann-Schwarz
et al. [17]
No. of specimens 285 80 37 42 51 (+13 other studies)
Histology
Borderline 18
1 (6%) 20
1 (25%) 0 0 8 (16%)
Carcinomas
Serous 246 (86%) 60 (75%) 37 (100%) 17 (41%) 31 (61%)
Endometrioid 20
1 (7%) 0 0 9 (21%) 8 (16%)
Clear Cell 0 0 0 7 (17%) 0
Mucinous 0 0 0 9 (21%) 4 (8%)
Adenocarcinoma (NOS) 1
1 (,0.1%) 0 0 0 0
Grade not specified not specified
1 11 (4%) 8 (10%) 3 (7%)
2 97 (36%) 0 8 (19%)
3 155 (58%) 72 (90%) 31 (74%)
unknown 4 (2%) 0 0
Stage not specified
I 16 (6%) 14 (18%) 0 16 (38%)
II 14 (5%) 0 0 5 (12%)
III 212 (79%) 58 (72%) Stage III & IV combined 18 (43%)
IV 21 (8%) 8 (10%) 37 (100%) 3 (7%)
unknown 4 (2%) 0 0 0
Tumor content of specimens $50% microdissected tumor tissue .80% not specified .75%
Normal tissue reference
2 10
3 10
3 6 5 4 whole ovaries
Microarray platform (Affy) U133 Plus 2.0 U133 Plus 2.0 U133 Plus 2.0 U95 GeneChip
No. differentially expressed genes 5868 3479 1084 86 69
1Borderline and non-serous cases in the Bonome and Tothill datasets were excluded from our analyses.
2Normal reference sample was ovarian surface epithelial brushings unless otherwise specified.
3The Tothill et al. [16] & Bonome et al. [14] datasets were compared to an identical normal reference sample.
doi:10.1371/journal.pone.0017617.t003
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publications) of prior reports in the literature implicating a role in
ovarian cancer, including NME1, whereas 13/27, 48% represent
novel candidates (Table 5).
Immunohistochemical validation of expression in ovarian
cancer and normal tissues
Eight candidate genes were selected from the list of 338 genes
regulated during the estrous cycle and dysregulated in ovarian
cancer for immunohistochemical validation on the basis of known,
probable or putative involvement in ovarian cancer as well as
availability of antibodies suitable for immunohistochemistry. Two
of our chosen genes, EPCAM and BIRC5, are known to be
overexpressed in ovarian cancer and may have therapeutic value
[17,26–29] and served as proof-of-principle in our analysis. Five
genes, MAPK1, SMARCA4, LCN2, PAK2 and EZH2 are known to
be involved in other cancer types [30–33] but there was little
evidence of their involvement in ovarian cancer.
The protein products of seven of the eight candidate genes were
found to be expressed in serous carcinomas. In general, expression
of the seven proteins in ovarian surface epithelium and inclusion
cysts was quite variable between cases, compared to fallopian tube
epithelium and ovarian cancer. EPCAM was expressed at low
levels in ovarian surface epithelium and consecutively higher levels
Table 4. Genes consistently dysregulated in the ovarian cancer expression datasets examined.
Fold change/direction of differential expression
Gene
1,2 EOC datasets
3
Tothill
et al. [16]
Bonome
et al. [14]
4
Donninger
et al. [15]
Lu et al.
[18]
Heinzelmann-Schwarz
et al. [17]
Upregulated Genes
CD24 5 68.6 47.7 56.2 .3u p
MAL2 5 3.4 3.0 3.1 .3u p
ESRP1 4 8.2 8.1 4.5 - up
EPCAM 4 7.6 10.4 38.9 - up
LRIG1 4 7.1 5.9 4.5 .3-
SPP1 4 7.0 2.6 - .3u p
WFDC2 4 6.2 17.7 - .3u p
MTHFD2 4 6.1 6.9 - .3u p
MUC1 4 5.1 6.1 4.1 .3-
CP 4 4.7 50.6 18.7 .3-
PRKCI 4 4.3 2.7 2.2 .3-
KPNA2 4 4.1 2.4 - .3u p
VEGFA 4 3.6 2.1 1.6 .3-
ERBB3 4 3.3 2.6 - .3u p
KIAA0101 4 2.6 7.3 - .3u p
SMC4 4 2.3 3.5 2.7 .3-
Downregulated Genes
ANXA8 3 223.6 225.6 234.4 na na
CALB2 3 221.8 247.6 257.8 na na
FAM153C 3 219.3 225.0 227.5 na na
REEP1 3 215.7 225.6 29.8 na na
C13orf36 3 215.4 220.0 214.6 na na
PCOLCE2 3 211.0 28.6 22.7 na na
LRRN4 3 210.0 26.3 28.2 na na
EFEMP1 3 29.2 216.5 28.4 na na
MUM1L1 3 28.6 221.7 25.9 na na
TCEAL2 3 28.5 229.4 212.8 na na
MNDA 3 27.6 224.4 28.8 na na
C8orf84 3 27.5 27.7 28.8 na na
DPYD 3 26.7 215.9 24.5 na na
FLRT2 3 25.5 230.3 215.3 na na
PDGFD 3 24.8 214.9 24.4 na na
1Full gene names can be found in Table S1.
2Genes sorted by number of ovarian cancer datasets showing dysregulation and fold change in Tothill et al. [16].
3Number of epithelial ovarian cancer (EOC) expression array datasets showing dysregulation. Two ovarian cancer datasets reported upregulated genes only [17,18].
4Fold change in late-stage, high grade ovarian cancer relative to normal controls.
doi:10.1371/journal.pone.0017617.t004
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seen in ovarian cancer (Figure 1 and Table 6). A similar pattern
was observed for EZH2 although expression in ovarian cancer was
similar to fallopian tube epithelium (Figure 1 and Table 6).
SMARCA4 was expressed at moderate to high levels in all tissues
tested (Figure 1) and BIRC5 staining was significantly higher in
fallopian tube epithelium and ovarian cancer compared to ovarian
surface epithelium and inclusion cysts (Figure 1 and Table 6).
Finally, PAK2 and MAPK1 were expressed at low to moderate
levels in all tissues tested (Figure 2). Overall, for the majority of
proteins, staining was higher in carcinomas compared with
ovarian surface epithelium, and in most cases (with the exception
of EPCAM), staining in carcinomas was at a similar level to that
seen in fallopian tube epithelium. LCN2 staining was not detected
at significant levels in the ovarian cancer cohort or in the
epithelium of normal tissues, despite expression being increased in
ovarian tumors in two expression array analyses [15,18]. Positive
staining was, however, seen inside a few inclusion cysts and in
intracytoplasmic vacuoles consistent with LCN2 being a secreted
protein (data not shown).
Pathways and gene ontologies
We analysed the predicted ontologies of the 338 gene set which
overlapped between ovarian cancer specimens and normal
ovarian surface epithelium and found over-representation of
processes involving protein folding, cytoskeleton, cell cycle and
cell adhesion (Table 7). We also analysed known cellular pathways
and found the pathways with the highest number of genes from the
Table 5. Subset of genes regulated during the murine estrous cycle and dysregulated in ovarian cancer.
Gene
1 Estrous Stage
2 EOC datasets
3 Direction of dysregulation
4 PubMed hits
5
EPCAM
6 PE 4 up 43
KIAA0101 PE/EM 4 up 0
NME1 PE 3 up 53
SPINT2 PE 3 up 24
PTK2 PE 3 up 24
EZR PE 3 down 13
GATA6 PE 3 down 12
CLDN3 PE 3 up 7
UBE2C PE 3 up 4
SLC34A2 PE 3 up 3
TPD52 PE 3 up 3
DHCR24 PE 3 up 1
PTPRF PE/EM 3 up 1
ARF1 PE 3 up 1
CYCS PE 3 up 0
HSPE1 PE 3 up 0
F11R PE 3 up 0
HMGB3 PE/EM 3 up 0
ATP11A PE 3 down 0
NUAK2
6 PE 3 up 0
CACYBP PE 3 up 0
PAK1IP1 PE/EM 3 up 0
NAA50 PE 3 up 0
SQLE PE 3 up 0
CTSC PE 3 up 0
C5orf34 EM 3 up 0
MUM1L1 PE 3 down 0
EZH2
6 PE 2 up 4
LCN2
6 PE 2 up 13
SMARCA4
6 PE 2 up 6
BIRC5
6 PE/EM 1 up 109
MAPK1
6 PE 1 up 78
1Full gene names can be found in Table S1.
2Estrous stage specific increase in expression (EM, estrus morning; PE, proestrus evening).
3Number of epithelial ovarian cancer (EOC) expression array datasets showing dysregulation.
4Direction of change in ovarian cancer relative to normal controls.
5Search terms were gene symbol as in Column 1 and ‘‘ovarian cancer or ovarian neoplasms [MeSH]’’ (PubMed accessed Sept 2009).
6Genes selected for immunohistochemical analysis.
doi:10.1371/journal.pone.0017617.t005
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reticulum stress and Ras signalling (Table 8). The most
significantly over-represented pathway is spindle assembly and
chromosome separation (Figure 3).
Genes in regions of copy number aberration
Our 338 gene set was further interrogated for genes found in
regions of copy number aberration in ovarian cancer using two
datasets – The Cancer Genome Atlas and Gorringe et al. [22].
Sixty four of 338 genes (19%) were found in regions of gain or loss
in both datasets. The direction of differential expression correlated
with copy number aberration for 39/64 genes (61%; p,0.05)
(Tables 9 and 10). Most genes which were amplified and
upregulated were grouped into 5 genomic regions – 1q, 3q, 8q,
12p and 20q (Table 9). Around half of the deleted and
downregulated genes were located on chromosomes 4q and 22q
(Table 10). There was a trend for genes within similar
chromosomal regions to be co-regulated. For example, 234
Figure 1. Candidate proteins with high expression in ovarian cancer. A. Representative photomicrographs of candidate protein expression
in ovarian surface epithelium (OSE), inclusion cyst (IC) and fallopian tube epithelium (FTE) from the same patient and epithelial ovarian cancer (EOC)
from a different patient in Cohort 1. B. Histoscores of immunostaining results. Significant differences in expression are marked by asterisks (p,0.05).
Statistically significant differences are outlined in Table 6.
doi:10.1371/journal.pone.0017617.g001
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the 20q group. Of these patients, 125 (53%) had amplification of
all genes in the 20q group (Table 9).
Commonly mutated cancer genes
We interrogated ovulation-related genes which were dysregu-
lated in ovarian cancer for genes commonly mutated in cancer by
comparison with data from Futreal et al. [24], Greenman et al.
[25] and COSMIC. The analysis in COSMIC was restricted to
genes that were i) regulated in the same direction in ovarian cancer
in at least three of the previously chosen studies or ii) identified in
either Futreal et al. [24], or Greenman et al. [25]. Based on these
analyses, we identified 25 genes regulated in mouse ovarian
surface epithelium and mutated in cancer including four genes,
SFPQ, TPM4, MSN and SUZ12 which form part of a fusion gene in
some cancers (Table 11).
NUAK2 (NUAK family, SNF1-like kinase, 2) was identified in
Greenman et al. [25] as a gene with a high probability of having a
‘driver’ mutation in both breast and ovarian carcinomas. We
confirmed protein expression of NUAK2 in normal ovarian tissue
and analysed the expression of NUAK2 in serous carcinoma,
Cohorts 1 and 2, which comprised 20 whole sections and 96 cases
on a tissue microarray, respectively. There were five cases
common between Cohorts 1 and 2. For these five cases, the
histoscore calculated for Cohort 2 was used in all analyses.
Amongst this cohort, expression was highly variable (Figure 4).
Overall, there were 33 (29%) high, 59 (52%) moderate and 22
(19%) low and there was no association between NUAK2
expression and FIGO stage or histological grade (data not shown).
Expression was highest in fallopian tube epithelium although this
was only statistically different to NUAK2 staining seen in ovarian
surface epithelium (p,0.05; Figure 4). A number of ovarian
cancer cases had lost expression relative to fallopian tube
epithelium, ovarian surface epithelium and inclusion cysts,
although staining in inclusion cysts was highly variable. Although
there was no a priori evidence to suggest NUAK2 may be
associated with outcome, we analysed the expression of NUAK2
for associations with progression-free or overall survival amongst
the cohort. We dichotomised the patient cohort at the median
histoscore and patients with lower NUAK2 expression had
reduced overall survival with median time to death of 22 months
compared to patients with higher NUAK2 expression who had
Figure 2. Candidate proteins with low to moderate expression
in ovarian cancer. A. Representative photomicrographs showing
candidate protein expression in ovarian surface epithelium (OSE),
inclusion cyst (IC) and fallopian tube epithelium (FTE) from the same
patient and epithelial ovarian cancer (EOC) from a different patient in
Cohort 1. B. Histoscores of immunostaining results. No statistically
significant differences were observed.
doi:10.1371/journal.pone.0017617.g002
Table 6. p-values of significant differences in antigen
expression between ovarian surface epithelium, inclusion
cysts, fallopian tube epithelium and ovarian cancer
1.
Histological Feature
Antigen
2 OSE IC FTE EOC
EPCAM IC 0.0001 -
FTE 0.0001 0.03 -
EOC 0.0001 0.0001 0.0001 -
EZH2 IC NS -
FTE 0.011 NS -
EOC 0.0001 0.035 NS -
BIRC5 IC NS -
FTE 0.02 0.02 - -
EOC 0.02 0.02 NS -
1Ovarian surface epithelium (OSE), inclusion cysts (IC) and fallopian tube
epithelium (FTE) were from the same patient and were assessed using a paired
t-test. Differences in expression between either OSE, IC or FTE from one set of
patients and epithelial ovarian cancer (EOC) from a second set of patients were
assessed using a one-way ANOVA with least squares difference post-hoc test.
NS, not significantly different.
2Full gene names can be found in Table S1.
doi:10.1371/journal.pone.0017617.t006
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with lower NUAK2 expression also tended to relapse earlier,
however we did not find a significant association between NUAK2
expression and progression-free survival.
Discussion
During the estrous cycle, ovarian surface epithelium undergo
cycles of trauma and proliferation with each ovulation accompa-
nied by hormonal surges and inflammation, which may cause
accumulation of genetic damage and ultimately lead to the
development of ovarian cancer [1]. Similar hormonal risk factors
have been associated with cancer arising in the fallopian tube [34].
In light of this hypothesis, we compared genes with regulated
expression in the normal mouse ovarian surface epithelium during
the estrous cycle [13], with genes reported to be aberrantly
expressed in ovarian cancer in five microarray studies. The five
chosen studies combined identified over 7000 genes differentially
expressed in ovarian cancer compared to normal ovarian surface
epithelium or whole ovaries. Furthermore, as has been previously
shown for other microarray datasets [35], there was very little
overlap between the five studies despite the similarities in study
design. Only MAL2 and CD24 were over-expressed in all 5
datasets. MAL2 is frequently overexpressed in breast carcinoma,
Table 7. Over-represented ontologies
1 among genes regulated during the estrous cycle and dysregulated in ovarian cancer.
Ontology Network p-value Genes
2
Protein folding in normal condition 2.4610
210 CABIN1; CCT3; CCT7; DNAJB1; DNAJB11; FKBP4; HDAC1; HSP90AA1;
HSP90B1; HSPA5/; HSPA9; HSPB1; HSPB8; HSPD1; HSPE1; HSPH1; PFDN2;
SERPINH1; ST13; STIP1
Response to unfolded proteins 1.1610
29 DERL1; DNAJB1; HSP90AA1; HSP90B1; HSPA5; HSPA9; HSPB1; HSPB8;
HSPD1; HSPE1; HSPH1; SERPINH1; UBE4B; XBP1
Actin filaments 2.8610
27 ACTN1; ACTR2; ARPC1B; CDC42; EZR; FBLIM1; MAPK1; MSN; MYO1C/;
MYO1E; PTK2; SPTAN1; TPM4
Spindle microtubules 3.8610
26 BUB1; CCNB1; DYNLL1; EPB41L1; ESPL1; KIF23; KPNB1; PTTG1; TUBA1B;
TUBB; TUBGCP2; UBE2C
Regulation of cytoskeleton rearrangement 3.4610
25 ACTN1; ARPC1B; CDC42; EZR; MAPK1; MSN TUBA1B; PTK2; SPTAN1;
TUBB
Mitosis 8.2610
25 ANAPC1; BIRC5; BUB1; CCNB1; DYNLL1; ESPL1; F11R; KIF23; KPNB1;
NCAPD2; PTTG1; TUBA1B; TUBB
Cell junctions 9.9610
25 ACTN1; FZR1; CLDN3; CLDN7; CTNNA2; KRT8; MAPK1; SPTAN1; TUBA1B;
TUBB; WNK4
Integrin-mediated cell-matrix adhesion 2.1610
24 ACTN1; CDC42; DCN; EZR; FBLIM1; JUN; MAPK1; MSN; PTK2; TUBA1B;
TUBB
Protein folding in ER and cytoplasm 3.3610
24 EZR/MSN; FKBP4; HSP90AA1; HSPA5; HSPA9; SERPINH1; UGGT1; XBP1
Phagosome in antigen presentation 4.0610
24 ACTN1; C3; CDC42; DERL1; EXOC5; EZR; HSP90AA1; HSP90B1; HSPA5;
HSPA9; JUN; MSN; PSMD2
1Ontology analysis performed using MetaCore software (St. Joseph, MI, USA).
2Full gene names can be found in Table S1.
doi:10.1371/journal.pone.0017617.t007
Table 8. Over-represented pathways
1 among genes regulated during the estrous cycle and dysregulated in ovarian cancer.
Pathway Category MetaCore Pathway Maps p-value Genes
2
Cell cycle Spindle assembly and chromosome separation 1.9610
25 ANAPC1; KPNB1; CCNB1; PTTG1; DYNLL1; TUBA1B;
ESPL1; TUBB2C
Apoptosis and survival Endoplasmic reticulum stress response pathway 3.3610
25 CYCS; JUN; DERL1; PDIA6; HSP90B1; XBP1; HSPA5
G-protein signaling Ras family GTPases in kinase cascades (scheme) 4.8610
25 CDC42; MAPK1; JUN; NRAS; KRAS
Immune response Alternative complement pathway 5.1610
25 C3
NA CFTR folding and maturation (norm and CF) 7.7610
25 DNAJB1; RPN1; HSP90AA1; UGCGL1; HSPA5;
HSPA9
Development Gastrin in cell growth and proliferation 9.2610
25 CDH1; STAT3; JUN; MAPK1; PTK2
Immune response Lectin induced complement pathway 1.9610
24 C3
Cell cycle Role of APC in cell cycle regulation 2.1610
24 ANAPC1; CCT7; BUB1; FZR1; CCNB1; CS; CCT3;
PTTG1
Immune response Classical complement pathway 2.6610
25 C3
Development Leptin signaling via JAK/STAT and MAPK cascades 8.4610
25 CYCS; MAPK1; SOCS3; STAT3
1Pathway analysis performed using MetaCore software (St. Joseph, MI, USA).
2Full gene names can be found in Table S1.
doi:10.1371/journal.pone.0017617.t008
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corresponding locus at chromosome 8q24.12. MAL2 binds tumor
protein D52 (TPD52), which is over-expressed in ovarian
carcinoma, and we have shown that MAL2 is frequently over-
expressed in all histological subtypes of ovarian cancer [36]. The
fold change in CD24 was remarkable with ,50-fold up-regulation
observed in three of the five chosen array studies which reported
fold change values. Cytoplasmic localisation of CD24 has been
shown to be associated with poor survival and CD24 has been
investigated as a therapeutic target in ovarian cancer [37,38].
Recently, CD24 has been investigated in the context of ovarian
cancer stem cells although the data are controversial as both the
presence and absence of CD24 has been shown to be associated
with a stem cell population in ovarian cancer [39,40].
Here we proposed an inter-study analysis combining results
from the five published microarray datasets with our dataset of
genes differentially expressed during the murine estrous cycle
[13], to address the hypothesis that genes involved in normal
Figure 3. Schematic diagram of most significantly over-represented pathway – spindle assembly and chromosome separation.
Genes with vertical red bars adjacent are those which we identified as being regulated during the estrous cycle and are upregulated in ovarian
cancer.
doi:10.1371/journal.pone.0017617.g003
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aberrantly expressed in ovarian cancer. Identification of this
subset may assist in prioritising human candidate genes and
pathways implicated in progression to ovarian cancer. We have
for the first time, identified genes and pathways that are regulated
in ovarian epithelium during the estrous cycle in vivo and aberrant
in ovarian carcinoma, and have accumulated evidence of
involvement in a subset of these genes in ovarian cancer
pathogenesis. Overall, 338 genes were found to be regulated
during the estrous cycle and dysregulated in human ovarian
cancer specimens. Importantly, this overlap was greater than
what would be expected by chance alone indicating that the
biological processes underpinning the estrous cycle and ovarian
cancer are very similar. The vast majority of genes in common
were upregulated in the ovarian epithelium of mice during
proestrus, just prior to ovulation, when the ovulatory surge results
Table 9. Genes regulated during the murine estrous cycle and with putative copy number gain and corresponding upregulation
in ovarian cancer.
Gorringe et al.
[22]
4 TCGA
5 TCGA - Broad data
6
Gene
1 Estrous Stage
2 EOC datasets
3 Genomic location Gain (% cases) Known CNA Gain (% cases)
Gain of all genes
in group (% cases
per group)
Genes on 1q 163/243 (67%)
CCT3 PE 2 1q23 36 - 44
CDC42SE1 PE 1 1q21.1 37 - 47
S100A6 PE 1 1q21 36 - 45
Genes on 3q 128/355 (36%)
DNAJB11 PE 2 3q27 51 - 64
PAK2 PE 2 3q29 47 true 58
SERP1 PE 2 3q25.1 43 - 56
IGF2BP2 PE/EM 1 3q27.2 52 - 66
ISY1 PE 1 3q21.3 31 - 41
RPN1 PE 1 3q21.3 32 true 41
Genes on 8q 148/321 (46%)
SQLE PE 3 8q24.1 57 - 65
PTK2 PE 3 8q24.3 55 true 61
TPD52 PE 3 8q21 32 - 39
DERL1 PE 2 8q24.13 54 - 63
Genes on 12p 107/236 (45%)
KRAS PE 2 12p12.1 32 - 40
FKBP4 PE 2 12p13.33 39 - 36
NCAPD2 EM 2 12p13.31 37 - 35
BCAT1 PE/EM 1 12pter-q12 32 - 39
MGST1 PE 1 12p12.3-p12.1 30 - 36
Genes on 20q 125/234 (53%)
UBE2C PE 3 20q13.12 37 - 39
EYA2 PE 2 20q13.1 41 true 41
AHCY PE 2 20q11.22 33 - 37
KIF3B PE 1 20q11.21 35 true 40
CTSA EM 1 20q13.12 37 - 38
TTPAL PE 1 20q13.12 34 - 38
EPB41L1 PE 1 20q11.2-q12 31 - 36
Remainder genes in amplified regions NA
CLPTM1L PE 2 5p15.33 31 - 36
BRD4 EM 1 19 29 true 37
1Full gene names can be found in Table S1.
2Estrus stage specific increase in expression (EM, estrus morning; PE, proestrus evening).
3Number of epithelial ovarian cancer (EOC) expression array datasets showing dysregulation.
4Patients (%) with gain (log2 CNA .0.3) based on meta-analysis by Gorringe et al. [22] (n=398).
5Position of gene within a known region of CNA as reported by TCGA (http://cancergenome.nih.gov).
6Patients (%) with gain (log2 CNA .0.3) based on data from TCGA (n=568).
doi:10.1371/journal.pone.0017617.t009
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ovulatory hormones in ovarian cancer pathogenesis.
Two genes, EPCAM and KIAA0101, up-regulated on the
evening of proestrus, were identified in four of the five human
ovarian cancer studies and 25 genes were identified in three of the
studies. The expression of genes originally identified in mice was
validated in human tissues by immunohistochemistry. We
validated the expression of eight genes with varying degrees of
evidence for involvement in ovarian cancer. We selected genes
with established roles in ovarian cancer (EPCAM, BIRC5), genes
with established roles in cancers other than ovarian cancer (EZH2,
SMARCA4) and genes with limited evidence for involvement in
cancer (MAPK1, PAK2). EPCAM and BIRC5 served as proof of
principle in our investigation since they are well known to be
overexpressed in ovarian cancer [41,42] and have been investi-
gated as therapeutic targets [43,44]. Our results in ovarian cancer
agree with previously published reports of high expression of
EPCAM localised to the membrane and high expression of BIRC5
evenly distributed between the cytoplasm and nucleus [42]. EZH2
and SMARCA4 are likely candidates to be associated with ovarian
cancer since they are amplified and/or overexpressed in a number
of cancers including prostate, gastric, and breast [33,45,46]. This
study is the first to demonstrate EZH2 and SMARCA4 expression
at a protein level in ovarian tissues. There is limited evidence for
the involvement of MAPK1 in cancer beyond in vitro studies while
PAK2 has been shown to be expressed in ovarian cancer in one
report and interacts with known cancer-associated genes [47,48].
Our data confirm that MAPK1 and PAK2 are expressed in
normal and malignant ovarian tissue.
The general pattern of low expression in ovarian surface
epithelium and higher expression in inclusion cysts seen in our
study has been previously reported in other studies [9]. It is
thought that high hormone levels in the ovarian stroma may
induce expression of a range of genes in the epithelium lining
inclusion cysts. We also observed a large variability in the
expression of our candidate proteins in normal ovarian surface
epithelium and inclusion cysts compared to that seen in fallopian
tube epithelium and ovarian cancer. Given that these genes were
originally identified as differentially expressed during the murine
estrous cycle, we would hypothesize that these genes are
hormonally regulated as has already been shown for BIRC5
[49,50]. The variability of expression seen in normal ovarian
surface epithelium and inclusion cysts may reflect the varying
hormonal status of the women in Cohort 1 at the time of tissue
collection. It is likely that some of the women in Cohort 1 are pre-
menopausal given that half the women are under 50 years of age,
however, the exact menopausal status of the women in Cohort 1 is
unknown.
An unexpected finding of this study is the relatively similar
expression of most of our candidate genes in fallopian tube
epithelium and ovarian cancer. It is possible that similar
expression of these genes is a reflection of the phenotypic similarity
between serous ovarian cancer and fallopian tube epithelium,
therefore, their contribution to ovarian tumorigenesis cannot be
discerned from our data. While expression levels in fallopian tube
epithelium and ovarian cancer were similar for most of our
candidate genes, it is important to note that those genes which
harbour mutations may exert a tumorigenic effect without an
Table 10. Genes regulated during the murine estrous cycle and with putative copy number loss and corresponding
downregulation in ovarian cancer.
Gorringe et al.
[22]
4 TCGA
5 TCGA - Broad data
6
Gene
1 Estrous Stage
2 EOC datasets
3 Genomic location Loss (% cases) Known CNA Loss (% cases)
Loss of all genes
in group (% cases
per group)
Genes on 4q 200/275 (73%)
FAT4 EM 2 4q28.1 35 - 51
PHF17 PE 2 4q26-q27 34 - 51
MAPKSP1 PE 1 4q24-q26 34 - 55
Genes on 22q 252/337 (75%)
ST13 PE 1 22q13.2 35 - 70
TEF PE/EM 1 22q13.2 34 true 70
HMOX1 PE 1 22q12 31 - 63
TIMP3 PE 1 22q12.3 34 - 61
Remainder genes in deleted regions NA
EZR PE 3 6q25.3 33 - 51
CIRBP PE/EM 2 19p13.3 34 true 77
EFNB3 EM 1 17p13.1 30 - 66
IGFBP4 PE/EM 1 17q12-q21.1 30 - 67
TK2 EM 1 16q22-q23.1 35 - 64
1Full gene names can be found in Table S1.
2Estrus stage specific increase in expression (EM, estrus morning; PE, proestrus evening).
3Number of epithelial ovarian cancer (EOC) expression array datasets showing dysregulation.
4Patients (%) with loss (log2 CNA ,20.3) based on meta-analysis by Gorringe et al. [22] (n=398).
5Position of gene within a known region of CNA as reported by TCGA (http://cancergenome.nih.gov).
6Patients (%) with loss (log2 CNA ,20.3 resp.) based on data from TCGA (n=568).
doi:10.1371/journal.pone.0017617.t010
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relevant for SMARCA4 which is mutated in many cancer cell
lines as well as patient samples [51] but was not significantly
overexpressed at a protein level in ovarian cancer compared to
normal tissues. LCN2 was not detected in our cohort of serous
ovarian cancer which is likely due to the predominance of high
grade cases in our cohort since Lim et al. [52] have shown that
LCN2 was expressed at low levels in high grade ovarian cancer but
moderate to strong levels in tumors of low grade and/or low
malignant potential.
Table 11. Genes regulated during the murine estrous cycle, aberrantly expressed in ovarian cancer and putatively mutated in
cancer.
Source of Mutation Data
5
Mutation/Fusion Data from COSMIC
6
Gene
1
Estrous
Stage
2
EOC
datasets
3
Direction of
dysregulation
4 Ref
Ovarian
cancer Other Cancers
Fusion gene partner
and site
Mutated in Ovarian Cancer
PTK2 PE 3 up - 0/26 1/476 CNS, 1/6 skin,
2/226 lung
NUAK2 PE 3 up [25] 1/26 1/82 breast
KRAS PE 2 up [24] 377/2754 mutations in
multiple organs
NRAS PE 2 up [24] 3/108 mutations in
multiple organs
SMARCA4 PE 2 up [24] 1/28 mutations in multiple
organs
CDH1 EM 1 up [24] 1/84 mutations in
multiple organs
BRD4 EM 1 up [24] 0/26 0/264
Mutated in Other Cancers
KIAA0101 PE/EM 4 up - - 1/22 CNS
MDM4 PE 3 inconsistent [24] - 1/447 CNS, 1/3
aerodigestive tract
SFPQ PE/EM 3 inconsistent [24] - 1/6 skin TFE3; kidney and soft
tissue
MALAT1 EM 3 down [24] no record
C5orf34 EM 3 up - - 1/48 breast
CYCS PE 3 up - - 1/11 lung
MUM1L1 PE 3 down - - 1/6 skin
GATA6 PE 3 down - - 3/446 CNS
TPM4 PE 2 up [24] - 1/48 breast ALK; haematopoietic and
soft tissue
EZH2 PE 2 up [24] - 58/690 haematopoietic
tissue, 1/38 intestine,
1/6 skin
JUN PE 2 up [24] - 0/783
FOXO1 PE 2 down [24] - 1/447 CNS
DICER1 PE/EM 1 up [24] - 1/11 lung, 1/6 skin
SUZ12 EM 1 up [24] - 0/171 JAZF1; endometrial and
soft tissue
HSP90AB1 PE 1 up [24] - 0/171
MSN PE 1 down [24] - 0/595 ALK; haematopoietic
tissue
RPN1 PE 1 up [24] no record
HNRNPA2B1 PE 1 down [24] no record
1Full gene names can be found in Table S1.
2Estrus stage specific increase in expression (EM, estrus morning; PE, proestrus evening).
3Number of epithelial ovarian cancer (EOC) expression array datasets showing dysregulation.
4Direction of change in ovarian cancer relative to normal controls.
5Mutation results based on data from Futreal et al. [24], Greenman et al. [25] and/or Catalogue of Somatic Mutations (COSMIC) database.
6Organs in which mutations have been found based on data from the Catalogue of Somatic Mutations (COSMIC) database.
doi:10.1371/journal.pone.0017617.t011
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significant over-representation of a number of processes and
pathways associated with tumorigenesis, including apoptosis, cell
adhesion and cell cycle. In total, 13 of the 27 genes identified in
three or more array datasets, have previously been described by
independent studies to be differentially expressed in ovarian
cancer specimens, including EPCAM, CLDN3, PTK2 and TPD52
while a further 11 genes have been investigated in the context of
other cancers. Interestingly, KIAA0101, CANX and NME1 have all
been found to be highly expressed in at least eight different
carcinomas, including breast, lung and prostate [53], representing
possible global tumor markers. However further work is required
to validate these results. The remaining three genes NAT13,
MUM1L1, C5orf34, however, have yet to be investigated in any
cancer to our knowledge thus validating our approach for the
purposes of identifying novel ovarian cancer-associated genes.
Of the genes found to be regulated during the estrous cycle and
mutated in cancers, 15 have been described in ovarian cancer
including KRAS which has an established role in ovarian cancer,
particularly in Type I tumors, that is low-grade ovarian cancer and
low malignant potential tumors [54]. In addition, FOXO1 is a
cisplatin sensitivity gene in cell lines [55] and MSN, was identified
as a novel diagnostic marker for distinguishing ovarian cancer
from colon cancer [56]. The remaining 10 genes have not been
investigated in ovarian cancer and include SFPQ which has been
suggested to function as an androgen receptor co-regulator [57].
These data provide further example of the potential utility of our
approach of using the ovarian surface epithelium gene signatures
to characterise genes and pathways implicated in ovarian cancer.
Based on our microarray and in silico analyses, NUAK2 is
regulated during the murine estrous cycle, dysregulated in ovarian
cancer and putatively contains a driver mutation in ovarian and
breast cancer. Although it has not been specifically investigated in
thecontextofcancer,thereisevidencethatNUAK2maybeinvolved
in cancer-associated pathways and may have pro-survival activity
[58]. We extended our immunohistochemical validation to an
ovarian cancer tissue microarray with ,100 specimens. This is the
first study to show NUAK2 expression in ovarian tissue.
Interestingly, a proportion of malignant cases expressed NUAK2
at reduced levels compared to normal fallopian tube epithelium and
inclusion cysts. Although our primary aim was to identify genes,
which may be involved in development of ovarian cancer,
aberrations in pathways which confer a survival advantage and
promote tumor development may also contribute to survival in
response to therapy and therefore may also be associated with
outcome. Indeed, expression ofNUAK2wassignificantly associated
with overall survival with median time to death differing by 20
months between median dichotomised groups of patients. Patients
with low NUAK2 expression fared worse than patients with high
expression of NUAK2. The putative driver mutation in NUAK2 and
association of loss of expression with reduced overall survival
suggests NUAK2 may have tumour suppressive activity. Our data
suggest that NUAK2 warrants further investigation in in vitro
functional models of ovarian cancer pathogenesis.
Our in silico analyses have identified a number of candidates
including genes with evidence of both copy number aberration and
mutation. Amongst these is KRAS which, as aforementioned, has an
established role in ovarian cancer [54]. Similarly, PTK2 is also
amplified in ovarian cancer and mutated in solid tumors.
Overexpression of PTK2 in ovarian cancer is significantly associated
with poorer survival [59] and PTK2 is being investigated as a
therapeutic target in xenograft models of ovarian cancer [60].
Amongst the genes with mutations in solid tumors is BUB1, for which
thereisnoexistingliteratureinthecontextofovariancancer.BUB1 is
a component of the spindle assembly checkpoint pathway which is
critical for ensuring correct chromosome segregation and prevention
of aneuploidy. The genes we identified which are regulated during
the estrous cycle and dysregulated in cancer are over-represented in
two pathways associated with spindle assembly. Defects in spindle
assembly checkpoint proteins, including BUB1, are sufficient to allow
proliferation of BRCA2 deficient cells which in the absence of a
‘‘second-hit’’ do not have a growth advantage [61]. While little work
has been done on BUB1 itself, other members of the spindle assembly
checkpoint have been investigated in the context of ovarian cancer
including BUBR1, which is an independent prognostic indicator for
ovarian cancer [62]. Furthermore, a functioning spindle assembly
checkpoint is required for sensitivity to microtubule inhibiting drugs
including paclitaxel which is widely used in ovarian cancer [63].
NCAPD2,ac a n d i d a t eg e n ew ei d e n t i f i e dw i t hc o p yn u m b e r
aberration and mutation, is a component of the condensin complex
w h i c hi si n v o l v e di nr e s o l u t i o na n ds e g r e g a t i o no fs i s t e rc h r o m a t i d s
during mitosis [64]. It is interesting that both BUB1 and NCAPD2
have emerged as candidate genes in our analyses which perhaps
indicates the importance of aberrations in the chromosomal
segregation pathway for ovarian cancer development.
Amongst genes we identified with copy number gain is ARPC1B
which is expressed in spontaneously transformed tumorigenic
mouse ovarian surface epithelial cell lines and is positively
correlated with tumor load in a mouse model of ovarian cancer
[65]. Ezrin, has been investigated in a large study of ovarian cancer
where its expression was reduced in 440 ovarian cancer samples
compared to normal and lower expression was associated with
higher grade and shorter survival although not in a multivariate
analysis [66]. Eyes absent 2 (EYA2) is upregulated in ovarian
cancer compared to normal ovarian surface epithelium in part due
to genomic amplification. EYA2 functions as a transcriptional
coactivator in ovarian cancer cell lines and ectopic expression of
EYA2 promotes growth of ovarian cancer xenografts. High
expression of EYA2 is significantly associated with a shorter
overall survival in late stage cancers [67]. The identification of
genes with at least putative roles in ovarian cancer validates our
approach of a multi-in silico analysis approach for prioritising
candidate genes for ovarian tumorigenesis. Another novel
candidate with copy number loss, CIRBP, is a cold-inducible
protein, however, it is also induced by UV irradiation and hypoxia
[68,69]. Evidence for a role for CIRBP in cancer is complex with
some studies indicating overexpression confers a growth advantage
[70] while others report downregulation or complete loss in tumor
tissue samples [71]. Interestingly while overexpression confers a
growth advantage, loss enhances sensitivity to DNA damaging
agents. In our analyses, CIRBP is downregulated in proestrus
evening and restored in estrus morning, downregulated in
expression array studies and lost in array CNA studies of ovarian
cancer. Given the limited evidence it is difficult to hypothesise a
role for CIRBP in ovarian cancer. However, it is tempting to
speculate that loss of CIRBP in ovarian surface epithelium may
Figure 4. Expression of NUAK2 in malignant ovarian tissue. A and B. Representative photomicrographs and histoscores summarising NUAK2
expression in normal ovarian surface epithelium (OSE), inclusion cysts (IC), fallopian tube epithelium (FTE) and epithelial ovarian cancer from both
Cohorts 1 and 2. C. Kaplan-Meier curves for progression-free and overall survival of ovarian cancer patients dichotomised at median NUAK2
expression. There was no association between NUAK2 expression and progression-free survival (p,0.133), however, lower NUAK2 expression was
associated with reduced overall survival (p,0.04) (log-rank test).
doi:10.1371/journal.pone.0017617.g004
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hormones thereby increasing risk of tumor initiation.
Using a data mining approach we have identified that genes
involved in the normal processes of the ovarian cycle may
constitute potentially important signalling pathways involved in
ovarian cancer. Taken together, these results further support the
existing evidence that genes involved in normal cellular pathways
during the ovulatory cycle, are also potential candidates in
epithelial ovarian carcinogenesis and worthy of additional
research.
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